Navigation Links
Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
Date:5/20/2008

lf of this year.

"There are still significant unmet needs in the treatment of COPD. These efficacy and safety data from the Phase II trials are very encouraging," said Lawrence S. Olanoff, M.D., Ph.D., President and Chief Operating Officer of Forest Laboratories. "We look forward to the completion of ACCLAIM I & II trials and continuing the clinical development of aclidinium for the treatment of COPD."

Additional Clinical Data

Three additional clinical trials assessing the safety and pharmacokinetics of aclidinium were also presented at this meeting.

A randomized, double-blind, placebo- and active-controlled clinical trial evaluating the cardiovascular safety and pharmacokinetics of aclidinium (200 or 800 mcg) in 272 healthy subjects, showed no effect on QT interval at doses up to 800 mcg. Furthermore, aclidinium was well-tolerated, with most adverse events being of mild intensity, related to electrode attachment, and of similar incidence across treatment groups. Maximum concentration of aclidinium was reached 5 to 30 minutes post-dose and aclidinium was not detectable in the plasma after one hour.

Results of two other randomized, placebo-controlled studies, each in 16 healthy subjects, were presented. In the first, subjects were exposed to single doses of aclidinium (600 -- 6000 mcg) and placebo to determine pharmacokinetics, safety and tolerability, and maximum tolerated dose. For all doses, aclidinium was undetectable in plasma beyond 3 hours post-dose. Aclidinium was well tolerated across this dosage range, with headache (n=10) and fatigue (n=5) being the most frequently reported adverse events. No serious adverse events were reported. The second study assessed the safety, tolerability, and pharmacokinetics of aclidinium after multiple doses. Subjects received 5 days of treatment with aclidinium 200, 400, 800 mcg or placebo. Aclidinium was undetectable in plasma after all studied doses beyond 1 hour post-dose. Aclidinium was we
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
2. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
3. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
4. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
5. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
8. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
9. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
10. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
11. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and ... third quarter 2014 financial results on Wednesday, October 29, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Wednesday, October 29 ...
(Date:10/17/2014)... Oct. 17, 2014  Training market researchers to ... success factor in today,s highly competitive global marketplace. ... organizations that effectively and efficiently produce high performing ... area. Effective training programs can ... recognition from internal clients by developing analysts who ...
(Date:10/17/2014)... DUBLIN , Oct. 17, 2014 ... of the "Research and Development Prospect of ... offering. Based on the 2013 ... Chinese government policies about dialysis industry and the ... in-depth research about dialysis industry segmentations. Moreover, it ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... StreamVenue Healthcare has partnered its "plug and play" ... Medicine to teach, and to better manage post-surgical patient ... surgeons and physical therapists to view cases and discuss ... cohesive communication and creates a live classroom for teaching ...
... Reportlinker.com announces that a new market research ... Middle East and Africa ENT Devices Market ... Middle East and Africa ENT ... Summary GlobalData,s new report, "Middle ...
Cached Medicine Technology:StreamVenue Healthcare Connects Endoscopy Technology With Athletic Trainers 2Reportlinker Adds Middle East and Africa ENT Devices Market Outlook to 2017 2
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... is known for being the sole manufacturer of the stem ... to go public//. The company is slated to sell out ... with the Securities and Exchange Commission. ,Stem cells have ... raging about what this science can really offer. Controversy has ...
... mothers are demanding that they be allowed to breastfeed babies ... weight behind this proposal saying that 'women should feel confident ... Kidney's Private Member's Bill has called for a breastfeeding law ... was passed in March. In a survey by the NCT, ...
... parents of junior athletes seem to have a negative impact ... in the British Journal of Sports Medicine. ,The ... junior tennis coaches in the US, which looked at the ... The coaches had all spent an average of 17 years ...
... Minister Tony Clement has said that anti-virals will be made ... This was part of Canada’s preparation efforts to combat a ... everyone who is ill to receive treatment. A strategy is ... will get them." ,Several programs have been initiated to ...
... thrombosis (DVT) occurs when people sit in the same position ... blood causing clots in the legs//. The condition can be ... lungs, causing a pulmonary embolism. DVT which has long been ... up with a solution called flip seats which give passengers ...
... there is no evidence to blame phones towers, the chief ... that chance// is a more likely explanation for the Melbourne ... any other environmental exposure. . ,Professor Coates explained that ... there is usually no cause every time they happen though ...
Cached Medicine News:Health News:Parents of Junior Athletes do More Harm than Good 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: